UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1159-9
Program Prior Authorization – Notification
Medication Solaraze (diclofenac 3% gel)
P&T Approval Date 8/2015, 7/2016, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Solaraze (diclofenac 3% topical gel) is indicated for the topical treatment of actinic keratosis
(AK). The recommended duration of therapy is from 60 to 90 days.
2. Coverage Criteriaa:
A. Authorization
1. Solaraze (diclofenac 3% topical gel)* will be approved based on the following criterion:
a. Diagnosis of actinic keratosis
Authorization will be issued for 3 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
*Applies to brand and generic Solaraze.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Diclofenac 3% topical gel (generic Solaraze) [package insert]. Bedminster, NJ: Alembic
Pharmaceuticals Limited; March 2023.
© 2024 United HealthCare Services, Inc.
1
Program Solaraze Prior Authorization – Notification
Change Control
Date Change
8/2015 New program.
7/2016 Updated references.
7/2018 Annual review. No changes.
7/2019 Annual review. No changes.
7/2020 Annual review. No changes.
7/2021 Annual review. Added state mandate language.
7/2022 Annual review. Updated references.
7/2023 Annual review. Added generic name due to brand unavailable. Updated
references.
7/2024 Annual review. Updated references.
© 2024 United HealthCare Services, Inc.
2